27/08/2024 | Press release | Archived content
On August 22, 2024, the U.S Food and Drug Administration (FDA) approved and authorized updated mRNA COVID-19 vaccines under an Emergency Use authorization. The updated vaccines are formulated to target currently circulating variants and to provide better protection against serious consequences of COVID-19, including hospitalization and death. These actions relate to updated mRNA vaccines for 2024-2025 manufactured by Moderna TX Inc. and Pfizer-BioNTech Inc., which have been updated to include a monovalent component that corresponds to the Omicron variant KP.2 strain.
On August 23, 2024, the Advisory Committee on Immunization Practices (ACIP) updated administration guidance for the Interim Clinical Considerations for the 2024-2025 COVID-19 mRNA vaccines.
The 2023-2024 Novavax COVID-19 vaccine remains authorized but is no longer available in the United States, as all doses have expired. Accordingly, at this time, the Centers for Disease Control and Prevention (CDC) recommendations for use of Novavax COVID-19 vaccine have been removed. CDC recommendations will be updated if FDA approves or authorizes additional 2024-2025 COVID-19 vaccines.
Administration and Ordering
2023-2024 mRNA COVID-19 Vaccines Are No Longer Authorized.
As part of FDA's actions, the 2023-2024 Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States. To minimize the risk of vaccine administration errors, providers should:
2024-2025 COVID-19 Vaccines for the VFC Program and 317 Program.
Please contact the ODH Immunization Program at 1-800-282-0546 or email [email protected] with questions.